Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.

Gene - 1 Dec 2013

Dadheech Sneha, Rao A Venkateswara, Shaheen Uzma, Hussien Mohammed Dyia, Jain Suman, Jyothy A, Munshi Anjana

Abstract excerpt

Deferiprone is used as a chelation agent in chronic iron overload in β-thalassemia patients. Patients on deferiprone therapy show variable response to this drug in terms of reduction in iron overload as well as adverse drug reactions (ADRs). The pharmacogenetic studies on deferiprone have not carried out in patients with blood disorders in India. Therefore, the present study was carried out to evaluate the three...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine
Share to beta-Thalassemia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Iron Chelating Agents

Share to Iron Overload

Share to Pyridones

Share to Serine

Share to Threonine

Source

Identifiers

PMID: 24036429
DOI: 10.1016/j.gene.2013.08.078

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.PMID 24036429Read ↗

UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.Semantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Semantic proximity Read ↗

Role of pharmacogenetics on deferasirox AUC and efficacy.Semantic proximity Read ↗

Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients.Semantic proximity Read ↗

Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion-Dependent Thalassemia Identified Using Whole-Genome Sequencing.Semantic proximity Read ↗

Clinical efficacy of thalidomide for various genotypes of beta thalassemiaSemantic proximity Read ↗

Association of CYP2C19 gene single nucleotide polymorphisms (rs12248560 and rs4244285) with response to thalidomide in transfusion dependent β-thalassemia patients- a 12-months follow-up study.Semantic proximity Read ↗

Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants.Semantic proximity Read ↗

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.Semantic proximity Read ↗

Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children.Semantic proximity Read ↗

Impact of SNP Variants in PON-1 or UGT1A1 on Iron Chelation Therapy Outcomes and Zinc Status in Thalassemia Major Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.